Seeking Alpha

RTI Biologics (RTIX -12.7%) gets smacked today after its Q4 EPS came in-line with forecasts, but...

RTI Biologics (RTIX -12.7%) gets smacked today after its Q4 EPS came in-line with forecasts, but revenue misses analyst estimates on weakness in its surgical specialties and sports medicine businesses. The company also issued downbeat guidance, saying sales and profit during the first half of the year will be weak due to customer reaction to its FDA warning letter over contaminated human tissue implants.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|